Exosomes: new molecular targets of diseases

Acta Pharmacol Sin. 2018 Apr;39(4):501-513. doi: 10.1038/aps.2017.162. Epub 2017 Dec 7.

Abstract

Extracellular vesicles (EVs) comprise apoptotic bodies, microvesicles and exosomes, and they perform as key regulators in cell-to-cell communication in normal as well as diseased states. EVs contain natural cargo molecules, such as miRNA, mRNA and proteins, and transfer these functional cargos to neighboring cells or more distant cells through circulation. These functionally active molecules then affect distinct signaling cascades. The message conveyed to the recipient cells is dependent upon the composition of the EV, which is determined by the parent cell and the EV biogenesis. Because of their properties such as increased stability in circulation, biocompatibility, low immunogenicity and toxicity, EVs have drawn attention as attractive delivery systems for therapeutics. This review focuses on the functional use of exosomes in therapy and the potential advantages and challenges in using exosomes for therapeutic purposes.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Carriers / chemistry
  • Drug Carriers / metabolism
  • Drug Carriers / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Exosomes / chemistry
  • Exosomes / drug effects*
  • Exosomes / metabolism
  • Exosomes / physiology*
  • Gene Transfer Techniques
  • Heart Diseases / physiopathology
  • Humans
  • Inflammation / physiopathology
  • Liver Diseases / physiopathology
  • Neoplasms / physiopathology
  • Neurodegenerative Diseases / physiopathology

Substances

  • Drug Carriers
  • Enzyme Inhibitors